Indegene Share News - Latest Updates, Live News & More

Latest news about Indegene

Indegene Limited Submits Q3FY26 IPO Monitoring Report with Rs. 703.32 Crore Utilization Jan 29, 2026

Indegene Limited submitted its Q3FY26 monitoring agency report showing Rs. 703.32 crore utilization from Rs. 760.00 crore IPO proceeds. Care Edge Ratings reported Rs. 29.15 crore deployment during the quarter, primarily for capital expenditure and inorganic growth. The company obtained shareholder approval for fund reallocation and maintains Rs. 56.68 crore in fixed deposits and bank accounts.

Indegene Limited Reports 30.8% Revenue Growth in Q3FY26 Results Jan 29, 2026

Indegene Limited Shareholders Approve Appointment of Independent Director Through Postal Ballot Jan 23, 2026

Indegene Limited Appoints Ms. Jill Mary De Simone as Independent Director for Three-Year Term Jan 22, 2026

Indegene Limited Schedules Board Meeting on January 29, 2026 for Q3FY26 Financial Results Review Jan 22, 2026

More news about Indegene

01Jan 26

Indegene Completes Amalgamation of Canadian Subsidiaries Effective January 2026

Indegene Limited announced the amalgamation of two Canadian step-down subsidiaries effective January 01, 2026, creating Indegene Healthcare Canada Inc. The transaction involves Indegene Aptilon Services Inc. and Trilogy Writing & Consulting Inc., with combined projected revenue of CAD 6.78 million, representing an internal restructuring to streamline Canadian operations.

31Dec 25

Indegene Limited Grants 5.08 Lakh RSUs to Employees Under 2020 Plan

Indegene Limited's Nomination and Remuneration Committee approved grants of 5,08,368 RSUs to eligible employees under the RSU 2020 Plan on December 31, 2025. The RSUs have an exercise price of ₹2.00 per share with a four-year vesting schedule of 25% annually. Employees have 75 days from each vesting date to exercise options, with the disclosure made in compliance with SEBI regulations.

31Dec 25

Indegene Limited Completes Acquisition of Trilogy Writing & Consulting Inc. for EUR 329,014

Indegene Limited completed an internal restructuring acquisition of 100% equity in Trilogy Writing & Consulting Inc. (Canada) for EUR 329,014 on December 31, 2025. The Canada-based medical writing company, which reported CAD 892,361 turnover in 2024, will become a wholly owned subsidiary of Indegene, Inc. following the cash transaction conducted on an arm's length basis.

11Nov 25

Indegene Expands European Footprint with EUR 8.5 Million Acquisition of Cake Group

Indegene Limited's subsidiary, Indegene Ireland Limited, is set to acquire Cake Group, a healthcare marketing agency in the DACH region, for up to EUR 8.50 million. The all-cash deal aims to strengthen Indegene's European footprint and enhance its healthcare communications capabilities. Cake Group, with 25 employees, has shown steady revenue performance, generating EUR 3.78 million in 2024. The acquisition, expected to complete in January 2026, is subject to Austrian regulatory approval.

04Nov 25

Indegene Reports 17.1% Revenue Growth in Q2 FY26, Announces Strategic Acquisitions

Indegene Limited posted robust Q2 FY26 results with revenue reaching ₹8,042.00 million, a 17.1% YoY increase. The company's EBITDA margin (adjusted) was 18.2%, with PAT at ₹1,021.00 million, up 11.4% YoY. Indegene announced two strategic acquisitions: BioPharm for $65 million and WARN & CO for GBP 2 million plus performance-linked payouts. The Enterprise segment grew by 8.1% QoQ, while Brand Activation saw a 15.8% decline. The company secured multiple large deals and increased its active customer base to 76. Indegene expects temporary EBITDA margin compression due to strategic investments but anticipates recovery in 6-8 quarters.

31Oct 25

Indegene Reports Strong Q2 FY26 Results with 17% YoY Revenue Growth

Indegene Limited posted strong Q2 FY26 results with revenue reaching INR 8,042.00 million, up 17.1% year-over-year. Adjusted EBITDA was INR 1,461.00 million with an 18.2% margin. The company acquired BioPharm for USD 104.00 million and WARN & Co. to enhance capabilities. Enterprise Commercial Solutions and Enterprise Medical Solutions segments showed growth of 26.2% and 13.4% respectively. Active client relationships increased to 76, and total employee count reached 5,245.

30Oct 25

Indegene Reports Strong Q2 Growth, Approves €8.5M Investment in Irish Subsidiary

Indegene Limited posted robust Q2 FY2025-26 results with revenue up 17% to ₹8.04 billion, net profit rising 11.2% to ₹1.02 billion, and EBITDA growing 11.9% to ₹1.41 billion year-over-year. The company's board approved an investment of up to €8.5 million in equity shares of its wholly owned subsidiary, Indegene Ireland Limited, to support capital expenditure and business expansion.

20Oct 25

Indegene Ltd Executes Significant Block Trade on NSE

A substantial block trade of Indegene Ltd shares occurred on the National Stock Exchange (NSE). The transaction involved 1,342,944 shares at Rs. 550.00 per share, totaling Rs. 73.86 crores. This significant movement of shares could potentially indicate a shift in ownership or a strategic move by a major stakeholder. The trade may have implications for market liquidity, reflect institutional interest, and potentially impact short-term price movements.

07Oct 25

Indegene Expands Precision Pharma Marketing with $104 Million BioPharm Acquisition

Indegene, a healthcare solutions provider, has acquired BioPharm for $104 million to enhance its precision pharma marketing capabilities. BioPharm boasts a 27% EBITDA margin on net revenue. The acquisition is expected to be EPS accretive after 5-6 quarters. Indegene has made an audio recording of the investor and analyst call discussing this acquisition available to the public.

01Oct 25

Indegene Expands AI-Driven Marketing Capabilities with $106 Million BioPharm Acquisition

Indegene's subsidiary, Indegene Ireland Limited, has signed an agreement to acquire BioPharm Parent Holding, Inc. and its subsidiaries for up to $106 million. This acquisition aims to enhance Indegene's omnichannel marketing capabilities and AI-driven marketing services for pharmaceutical companies. BioPharm, a specialized marketing agency serving top biopharma organizations, reported revenues of $38.13 million. The deal is expected to close by October 1, 2025, bringing over 90 US-based employees to Indegene.

24Sept 25

Indegene's Digital Summit 2025 Spotlights AI-Powered Life Sciences Commercialization

Indegene Limited hosted its 7th annual Digital Summit 2025 in Philadelphia, exploring AI's impact on life sciences commercialization. The event, themed 'From Chaos to Clarity - and Better Decisions', covered topics like Generative AI applications, data unification, and zero-rep commercial models. The summit also featured the Vital Awards, recognizing industry innovators in four categories: Patient Impact, Community Impact, Organizational Impact, and Market Impact. Award recipients included executives from AstraZeneca, Merck, and Sanofi. The event is part of Indegene's #FutureReadyHealthcare initiative, aiming to promote collaboration and thought leadership in the life sciences industry.

19Sept 25

Indegene Partners with Datavant to Revolutionize Clinical Trial Recruitment

Indegene Limited has formed a strategic partnership with Datavant to improve patient recruitment for clinical trials, especially for rare diseases and complex studies. The collaboration integrates Datavant's data enrichment capabilities into Indegene's NEXT Patient Recruitment platform. Datavant's network covers over 80,000 hospitals and clinics, processing more than 100 million patient records annually. The partnership aims to streamline participant identification, accelerate trial enrollment, reduce screen failures, and improve screen-to-randomization ratios. This data-driven approach is expected to benefit both patients and pharmaceutical companies by connecting suitable participants with relevant trials more efficiently.

05Sept 25

Indegene Expands India Footprint with New Center in Pune

Indegene Limited, a digital-first life sciences commercialization company, has opened a new center in Pune, India. This expansion aims to leverage the city's skilled technology, management, and medical talent pool to enhance the company's global client services. Indegene serves top biopharma companies, biotech firms, and medical device companies, operating across 9 hubs and 20 offices worldwide with about 5,000 employees. The company focuses on providing digital-first, personalized, and omnichannel experiences for patients and physicians in the healthcare sector.

13Aug 25

Indegene Limited Shareholders Overwhelmingly Approve IPO Proceeds Reallocation

Indegene Limited's shareholders have approved a special resolution to modify the utilization of Initial Public Offering (IPO) proceeds through a remote e-voting postal ballot. The resolution received overwhelming support with 99.99% of votes in favor, representing 38.53% of the company's outstanding shares. The e-voting process, conducted from July 14 to August 12, 2025, was overseen by a Practicing Company Secretary as the Scrutinizer. The voting results and Scrutinizer's report have been made publicly available on the company's website and the National Securities Depository Limited's website.

06Aug 25

Indegene Reports 1.8% USD Revenue Growth in Q1, Launches Tectonic Initiative

Indegene Limited reported Q1 financial results showing steady growth. Revenue reached INR 7,068.00 million, up 1.8% in USD terms. EBITDA stood at INR 1,536.00 million, with 0.7% quarter-on-quarter growth. The company introduced 'Tectonic', a new commercial content creation initiative, generating over USD 1.00 million in revenue. Enterprise segments contributed 86.6% of revenue, growing 3.5% quarter-on-quarter, while Brand Activation segment experienced a 21.6% degrowth. Indegene secured multiple large deal wins and is actively incorporating AI into its solutions through its Cortex platform.

31Jul 25

Indegene Reports 1.8% QoQ Revenue Growth, Unveils Strategic Growth Initiatives

Indegene Limited announced Q1 FY26 results with consolidated revenue of ₹7,608 million, up 12.5% YoY. EBITDA margin stood at 20.2% and PAT margin at 15.3%. The company outlined strategic initiatives including the Tectonic program, sales reorganization, capability enhancement, consulting practice repositioning, operational excellence implementation, and M&A focus. Enterprise Commercial Solutions segment grew 4.6% QoQ, while Brand Activation saw a 21.6% decline due to project delays.

31Jul 25

Indegene Limited Reports Strong Q1 Performance with 32.7% Profit Growth

Indegene Limited reported robust financial results for Q1 FY24 ended June 30. Revenue from operations increased by 12.5% year-over-year to ₹7,608.00 million. EBITDA grew by 15.7% to ₹1,536.00 million, with a margin of 20.2%. Profit after tax surged by 32.7% to ₹1,164.00 million. Enterprise Commercial Solutions and Enterprise Medical Solutions segments showed strong growth of 18.8% and 12.8% respectively. The company's 'Tectonic' initiative has started generating revenue, and Indegene maintained strong client relationships with 40 clients contributing over $1 million in revenue.

30Jul 25

Indegene Recognized as Leader in Life Sciences AI and Analytics by Everest Group

Indegene Limited has been recognized as a Leader in Life Sciences AI and Analytics Services for Commercial PEAK Matrix® Assessment 2025 by Everest Group. The company was commended for its comprehensive AI and Analytics solutions, deep domain expertise, and innovative integration of Generative AI and Agentic AI capabilities. Indegene's global presence and specialized therapy area solutions were also highlighted as key strengths. The assessment evaluated 30 service providers, with Indegene standing out for its ability to deliver contextualized commercial solutions across various therapy areas.

30Jul 25

Indegene Recognized as Leader in Life Sciences AI and Analytics by Everest Group

Indegene Limited has been recognized as a Leader in Life Sciences AI and Analytics Services for Commercial PEAK Matrix® Assessment 2025 by Everest Group. The company's expertise in combining AI and Analytics with domain knowledge in specialty care, oncology, and rare diseases was highlighted. Indegene's unified AI approach aims to help life sciences companies achieve operational efficiencies and productivity gains. The assessment was based on vision, capabilities, and market impact among 30 service providers.

24Jul 25

Indegene Limited Sets Board Meeting for Q1 FY26 Results and ESOP Allotments

Indegene Limited has scheduled a board meeting for July 31, 2025, to review Q1 FY26 financial results and approve ESOP allotments. The company has closed its trading window from July 1, 2025, until 48 hours after results declaration. An earnings conference call is set for August 1, 2025, at 9:00 AM IST, featuring CEO Manish Gupta and CFO Suhas Prabhu.

23Jul 25

Indegene Limited Clarifies Spanish Subsidiary Acquisition Details

Indegene Limited disclosed details of its acquisition of Climacreative Spain S.L.U through its Irish subsidiary for €5,500. The acquisition, aimed at establishing presence in Spain, was made on November 19, 2024. The company acknowledged an inadvertent omission in filing the disclosure under SEBI regulations and reaffirmed its commitment to corporate governance standards. The acquired entity, now renamed Indegene Spain S.L.U, was a shelf company with no prior operations.

23Jul 25

Indegene Limited Clarifies Inadvertent Omission in Spanish Subsidiary Acquisition

Indegene Limited has provided additional details about its acquisition of Climacreative Spain S.L.U, a shelf company, through its Irish subsidiary for €5,500. The acquisition, made on November 19, 2024, was aimed at establishing a presence in Spain. The company addressed an unintentional oversight in its initial regulatory disclosure, emphasizing that the transaction was non-material and not related to any party. This move aligns with Indegene's European expansion strategy.

23Jul 25

Indegene Limited Discloses Inadvertent Omission in Spanish Subsidiary Acquisition

Indegene Limited has provided additional details about its acquisition of Climacreative Spain S.L.U, a shelf company, through its wholly-owned subsidiary Indegene Ireland Limited. The acquisition, completed on November 19, 2024, for €5,500, was aimed at establishing a presence in Spain. The company acknowledged an inadvertent delay in disclosing this information and emphasized that the acquired entity had no prior business operations or turnover. The Spanish subsidiary has since been renamed Indegene Spain S.L.U.

22Jul 25

Indegene Limited Reappoints Neeraj Bharadwaj as Independent Director for 5 Years

Indegene Limited announced the reappointment of Mr. Neeraj Bharadwaj as Non-Executive Independent Director for a five-year term effective January 25, 2026. The Harvard MBA graduate brings extensive experience in private equity and investment management. The board also approved ESOP and RSU plan allotments during the same meeting.

11Jul 25

Indegene Unveils NEXT: A GenAI-Powered Medical Writing Automation Platform

Indegene has introduced NEXT Medical Writing Automation, a platform combining medical writing expertise with generative AI technology. The tool aims to streamline medical writing workflows across clinical development and regulatory submissions. It integrates with existing systems, boosts efficiency through automated scheduling and task assignments, and maintains compliance. The platform is powered by Indegene's Cortex AI engine and is designed to elevate the practice of medical writing by allowing writers to focus on strategic tasks while automating data and formatting processes.

13Jun 25

Indegene Ltd. Sees Significant Block Trade Worth ₹106.63 Crore on NSE

A significant block trade of 1,804,900 shares of Indegene Ltd. was executed on the National Stock Exchange (NSE) at ₹590.80 per share, totaling ₹106.63 crore. This large transaction could indicate institutional investor activity or potential changes in ownership structure. Indegene Ltd. is a technology-led healthcare solutions provider offering digital transformation services for healthcare organizations.

05Jun 25

Indegene Shares Change Hands as Carlyle Exits; Major Funds Step In

Indegene Ltd experienced a significant change in its shareholding pattern through a block deal. Several prominent investment funds, including Abakkus Emerging Opportunities Fund, East Bridge Capital Master Fund, Societe Generale, Smallcap World Fund, and PI Opportunities AIF, acquired stakes in the company. Simultaneously, private equity firm Carlyle completely exited its 10.56% stake, selling shares at an average price of ₹591.00 per share.

05Jun 25

Indegene Shares See Major Acquisitions by Abakkus Fund and Societe Generale

Abakkus Emerging Opportunities Fund-1 purchased 12.10 lakh shares of Indegene at ₹591.48 per share through open market transactions. Simultaneously, Societe Generale acquired 18.80 lakh shares at ₹591.00 per share. The combined acquisition of 30.90 lakh shares by these two entities represents a substantial transaction volume for Indegene, potentially signaling investor confidence in the company's prospects.

04Jun 25

Carlyle Group Exits Indegene with Rs 1,447 Crore Stake Sale

Carlyle Group has divested its entire 10.2% stake in Indegene, a healthcare technology company, through open market operations for Rs 1,447.00 crore. The transaction involved selling over 2.44 crore shares at Rs 591.02 to Rs 591.84 per share. New investors, including Premji Invest, Capital Group, Societe Generale, Eastbridge Group, and Abakkus Asset Manager, have collectively acquired a 4.42% stake for approximately Rs 627.00 crore.

04Jun 25

Indegene Ltd: Carlyle Affiliate Offloads 10.5% Stake in Block Deal

CA Dawn Investments, an affiliate of Carlyle Group, sold a 10.5% equity stake in Indegene Ltd through block deals on June 4. The transaction involved approximately 2.44 crore shares at a floor price of ₹580.00 per share, potentially raising ₹1,420.00 crore. This follows a previous 4.7% stake sale in December, indicating a strategic realignment of ownership in the healthcare technology company.

04Jun 25

Indegene Shares Witness Massive Block Trade Worth ₹1,461 Crore on NSE

A significant block trade of approximately 24.67 million Indegene shares occurred on the National Stock Exchange. The shares were traded at ₹592.25 each, totaling ₹1,461.16 crore. This transaction represents a substantial portion of Indegene's outstanding shares and may indicate a shift in the company's ownership structure. The trade could impact investor confidence, market liquidity, and potentially influence short-term price movements of the stock.

03Jun 25

Carlyle Affiliate to Offload 10.2% Stake in Indegene Ltd for ₹1,420 Crore

CA Dawn Investments, an affiliate of Carlyle, plans to sell a 10.2% stake in Indegene Ltd through a block deal. The transaction involves 2.44 crore shares at a floor price of ₹580 per share, representing a 6.4% discount to the current market price. The deal, valued at approximately ₹1,420 crore, is being facilitated by Kotak and IIFL. This divestment could impact Indegene's ownership structure, market liquidity, and attract new institutional investors.

03Jun 25

CA Dawn to Offload 10.2% Stake in Indegene for ₹1,420 Crore

CA Dawn plans to divest a 10.2% stake in Indegene, a healthcare technology company, through a block deal. The floor price is set at ₹580.00 per share, with the deal valued at approximately ₹1,420.00 crore. This significant ownership change is expected to impact Indegene's shareholding pattern and potentially influence its stock price and trading volume.

29Apr 25

Indegene Reports Strong Q4 FY25 Results with 12.3% YoY Revenue Growth and 15.6% PAT Margin

Indegene Limited announced its Q4 and FY25 financial results, showing robust growth. Q4 revenue increased 12.3% YoY to ₹7,556.00 million, with PAT up 24.0% to ₹1,176.00 million. Full-year revenue grew 9.6% to ₹28,393.00 million, while PAT rose 20.8% to ₹4,067.00 million. The company maintained strong EBITDA margins and improved PAT margins. Segment-wise, Enterprise Medical Solutions showed the highest growth at 31.5% YoY. Indegene completed its IPO, raising ₹7,600.00 million, and announced a maiden dividend of ₹2.00 per share. The acquisition of MJL Communications Group Ltd is expected to enhance the company's capabilities.

28Apr 25

Indegene Reports Robust Q4 Performance: Net Profit Surges 24% YoY, Declares Final Dividend

Indegene Limited announced impressive Q4 FY2025 financial results, with consolidated net profit up 24% to ₹1.18 billion and revenue increasing 13% to ₹7.56 billion year-over-year. For the full fiscal year 2025, the company's revenue grew 9.6% to ₹28,393.00 million, while net profit surged 20.8% to ₹4,067.00 million. The Enterprise Medical Solutions segment showed significant growth of 33.6%. The company maintains a strong financial position with increased investments and has recommended a final dividend of ₹2.00 per equity share.

26Mar 25

Indegene's Irish Subsidiary Set to Acquire MJL Communications Group for £3.4 Million

Indegene Limited is set to acquire MJL Communications Group Ltd. and its subsidiary through its Irish subsidiary for up to £3.40 million. The all-cash deal, expected to complete by March 31, 2025, aims to strengthen Indegene's presence in Europe, particularly in the UK and EU markets. MJL Communications, a healthcare communications and advertising firm founded in 1982, reported provisional revenue of £1.92 million in 2024. This strategic move is anticipated to create synergies and support Indegene's long-term growth in the healthcare communications sector.

25Mar 25

Indegene's Irish Subsidiary to Acquire MJL Communications Group for £3.4 Million

Indegene Limited's Irish subsidiary is set to acquire MJL Communications Group Ltd. and its subsidiary for up to £3.4 million. The phased acquisition, expected to complete by March 31, 2025, aims to strengthen Indegene's European presence. MJL Group, a UK-based healthcare communications agency, specializes in brand creation, omnichannel campaigns, and healthcare initiatives. The all-cash deal includes potential earnouts and adjustments, aligning with Indegene's long-term growth strategy in the UK/EU market.

24Feb 25

Indegene Unveils Cortex: A Groundbreaking Generative AI Platform for Life Sciences

Indegene Limited has introduced Cortex, a generative AI platform tailored for the life sciences industry. Cortex incorporates 25+ years of industry expertise, offers flexible LLM integration, and enables multi-agent orchestration. The platform aims to streamline content supply chains, enhance medical writing, and accelerate MLR reviews. It promises faster turnaround times, better ROI, and improved accuracy compared to industry-agnostic platforms. Indegene's efforts in GenAI have been recognized by HFS Research and Everest Group.